Skip to main content

Table 5 OS according to clinicophathological characteristics

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

Mean OS (95% CI)a (months)

p-value

Overall

9.2 (5.3–13.2)

 

Age (years)

≤ 70

6.1 (0.3–11.8)

0.27

> 70

10.0 (7.2–12.8)

Gender

Male

8.9 (5.1–12.8)

0.76

Female

9.2 (2.3–16.1)

Histology

Adenocarcinoma

9.2 (4.6–13.9)

0.56

Squamous

9.8 (2.5–17.2)

PS ECOG

0

9.2 (5.6–12.8)

0.65

> 1

2.0 (0.1–5.4)

Smoke

Never smoker

9.9 (0.1–20.5)

0.80

Smoker

8.9 (4.7–13.2)

Prior treatment lines, n

1

6.1 (3.6–8.5)

0.036

≥ 2

12.2 (8.2–13.3)

RECIST response

No response

6.4 (4.8–8.0)

< 0.001

Response

13.5 (11.2–15.7)

  1. aMedian survival not reached